Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?
AUSTIN, Texas — Patients with AKI self-reported a high level of physical and emotional burdens, revealing fatigue to be one of the most common symptoms, according to a presenter at the National Kidney Foundation Spring Clinical Meetings.“We were interested in patient-reported outcomes, like the symptom burden and self-reported quality of life, among survivors of acute kidney injury